Activation of the immune system of cancer patients by continuous i.v. recombinant IL-2 (rIL-2) therapy is dependent on dose and schedule of rIL-2.

Add item related to this paper

  • MiniManuscript ID
    1776
  • Pubmed ID
    8485906